Cipla
Mumbai, Maharashtra, India · Biotechnology, Health Care, Manufacturing
Cipla is a global pharmaceutical company based in India. The company specializes in the production and distribution of a wide range of medications, including generic and branded drugs. Cipla is committed to providing accessible healthcare solutions and has a presence in many international markets.
Key facts
- Headquarters
- Mumbai, Maharashtra, India
- Employees
- 28,000
- Industries
- Biotechnology, Health Care, Manufacturing
- Website
- cipla.com
- Company page
Recent activity at Cipla
- : Cipla partners with Qilu Pharma to exclusively commercialize QL2107, a biosimilar to pembrolizumab, in the US.
- : Cipla Forms Exclusive Partnership with Qilu Pharmaceutical for Biosimilar Keytruda® in the US.
- : Cipla Appoints Dinesh Jain as Chief Financial Officer
- : Cipla Appoints Arun Kakatkar as Global Chief People Officer
- : Cipla partners with Pfizer for exclusive marketing of four Pfizer brands in India.
- : Cipla Appoints Achin Gupta as Global CEO Succeeding Umang Vohra
- : Cipla Appoints Achin Gupta as Global Chief Operating Officer (GCOO)
- : Indian Pharma Companies Forge Strategic Alliances in Diabetes Management
- : Cipla Limited Appoints Maya Hari as CEO and Sharmila Paranjpe as CFO
Leadership
- Umang Vohra, Managing Director & Global CEO
- Raju Mistry, President and Global Chief People Officer
- Dinesh Jain, Chief Financial Officer
- Achin Gupta, Chief Executive Officer
- Arun Kakatkar, Global Chief People Officer
Verified email and direct lines for Cipla’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Cipla in the news
- India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar - Reuters (Sep 03, 2026)
- Cipla Receives U.S. FDA Approval for Generic Advair Diskus® - Yahoo Finance (Jul 28, 2026)
- Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US - PR Newswire (Sep 03, 2026)
- Cipla Launches Afrezza in India: Revolutionizing Diabetes Care with Needle-Free Inhaled Insulin - Medical Dialogues (Mar 11, 2026)
- Cipla Pharma license cancellation order withdrawn as HC chides Maharashtra FDA - BusinessLine (Aug 29, 2026)
- Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India - Reuters (Jun 21, 2024)
- Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA - PR Newswire (Apr 23, 2026)
- Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis - Yahoo Finance (Apr 02, 2026)
Companies similar to Cipla
- Dr. Reddy's Laboratories · Biotechnology, Health Care, Manufacturing, Pharmaceutical, pharmaceuticals
- Teva Pharmaceutical Industries Ltd · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Bristol Myers Squibb · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Mylan · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Glenmark Pharmaceuticals · Biotechnology, Manufacturing, Pharmaceutical, pharmaceuticals
About Cipla: questions and answers
What does Cipla do?
Cipla is a global pharmaceutical company based in India. The company specializes in the production and distribution of a wide range of medications, including generic and branded drugs. Cipla is committed to providing accessible healthcare solutions and has a presence in many international markets.
Where is Cipla headquartered?
Cipla is headquartered in Mumbai, Maharashtra, India.
How many employees does Cipla have?
Cipla has about 28,000 employees.
Who leads Cipla?
Umang Vohra is a Managing Director & Global CEO at Cipla.
What is the latest news on Cipla?
On Sep 04, 2026, Cipla partners with Qilu Pharma to exclusively commercialize QL2107, a biosimilar to pembrolizumab, in the US.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy